Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.30
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 0.20 (2.151%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.40
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Dec 2017 14:31

RNS Number : 6798Z
e-Therapeutics plc
18 December 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

e-Therapeutics PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Non-renounceable entitlement offer & institutional placement

X

3. Details of person subject to the notification obligationiv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United-Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15/12/2017

6. Date on which issuer notified (DD/MM/YYYY):

18/12/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.97%

11.97%

268,471,406

Position of previous notification (if

applicable)

12.13%

12.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B2823H99

32,142,027

11.97%

SUBTOTAL 8. A

32,142,027

11.97%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, United-Kingdom

Date of completion

18/12/2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEALAPFAAXFFF
Date   Source Headline
21st Jun 201612:59 pmRNSIssue of Equity
7th Jun 20162:08 pmRNSIssue of Equity and Directors' shareholdings
1st Jun 20167:00 amRNSSearchbolt Offer becomes wholly unconditional
27th May 20163:18 pmRNSResult of General Meeting
25th May 20162:59 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
13th May 20164:08 pmRNSNotice of General Meeting - Correction
12th May 201610:50 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSProposed Acquisition of Searchbolt, Notice of GM
15th Apr 201612:19 pmRNSNotice of AGM and Annual Report
22nd Mar 20167:00 amRNSFinal Results
4th Mar 20167:00 amRNSNotice of Results
15th Feb 20167:00 amRNSTop-line Phase IIb results update
6th Jan 20167:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20153:38 pmRNSHolding(s) in Company
30th Nov 20154:48 pmRNSHolding(s) in Company
29th Oct 20157:00 amRNSAppointment of Non-Executive Director
29th Sep 20157:00 amRNSHalf Yearly Report
17th Sep 20157:05 amRNSNotice of Half Year Results
17th Sep 20157:00 amRNSChange of Nominated Adviser and Broker
10th Sep 20159:00 amRNSDirector's Disclosure
17th Aug 20157:00 amRNSHalf year trading and commercial strategy update
19th Jun 20158:38 amRNSExercise of Options
11th Jun 201511:31 amRNSResult of AGM
11th Jun 20157:00 amRNSAGM Statement
21st May 20157:00 amRNSProgress in ETS2101 Phase Ib Study
7th May 20157:00 amRNSNotice of AGM and Annual Report
31st Mar 20157:00 amRNSFinal Results
11th Mar 20154:08 pmRNSHolding(s) in Company
11th Mar 201512:41 pmRNSHolding(s) in Company
10th Mar 20157:03 amRNSNotice of Full Year Results
6th Mar 20152:22 pmRNSHolding(s) in Company
26th Feb 20151:55 pmRNSStmnt re Share Price Movement
21st Jan 201511:20 amRNSDirector/PDMR Shareholding
7th Jan 20157:00 amRNSAwards made under Performance Share Plan
7th Jan 20157:00 amRNSIssue of Equity
5th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSe-Therapeutics' Impact is rated World Class
18th Dec 20147:00 amRNSUpdate: ETS2101 Phase 1a and Oral Dosing Studies
27th Nov 20147:00 amRNSResearch and Development presentation to Investors
16th Oct 20148:35 amRNSAppointment of Executive Director
16th Sep 20147:00 amRNSHalf Yearly Report
4th Sep 20142:55 pmRNSNotice of Results
5th Aug 20147:00 amRNSAdditional Listing
1st Aug 20149:22 amRNSIssue of equity and Directors' shareholdings
9th Jul 201411:31 amRNSAGM Statement
9th Jul 20147:00 amRNSAwards made under Performance Share Plan
4th Jul 20147:00 amRNSDirector/PDMR Shareholding
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.